Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

3.210 -0.100 (-3.02%)
Streaming Delayed Price Updated: 9:46 AM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,057
Open 3.280
Bid (Size) 3.200 (100)
Ask (Size) 3.300 (200)
Prev. Close 3.310
Today's Range 3.200 - 3.280
52wk Range 2.550 - 5.744
Shares Outstanding 11,184,423
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
From Lantern Pharma Inc.
Via Business Wire

Performance

YTD
+3.2%
+3.2%
1 Month
-5.9%
-5.9%
3 Month
-19.3%
-19.3%
6 Month
-17.1%
-17.1%
1 Year
-30.1%
-30.1%

More News

Read More
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Establishes AI Center of Excellence and Advanced Agentic Labs in India
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television
Via ACCESS Newswire
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Lantern Pharma Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Lantern Pharma Earnings Preview ↗
Via Benzinga
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST
Via ACCESS Newswire
News headline image
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows
Via ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 30
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Advancing Drug Discovery with PredictBBB.ai(TM) Partnership
Via Investor Brand Network
Topics Artificial Intelligence
MissionIRNewsBreaks – RADR(R) Platform Powers Lantern Pharma Inc.’s (NASDAQ: LTRN) Push Into Rare Pediatric Brain Cancer Treatment
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?
Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
What exchange does Lantern Pharma Inc. - Common Stock trade on?
Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
What is the current price of Lantern Pharma Inc. - Common Stock?
The current price of Lantern Pharma Inc. - Common Stock is 3.210
When was Lantern Pharma Inc. - Common Stock last traded?
The last trade of Lantern Pharma Inc. - Common Stock was at 01/28/26 09:46 AM ET
What is the market capitalization of Lantern Pharma Inc. - Common Stock?
The market capitalization of Lantern Pharma Inc. - Common Stock is 35.90M
How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
Lantern Pharma Inc. - Common Stock has 36M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.